Ann: Botanix $70 Million Institutional Capital Raising, page-132

Also can others please confirm or comment on the below:

Here's the sales curve for Japan:
Fy 2021 950 million yen
Fy 2022 1,257 million yen
Fy 2023 1,812 million yen
Fy 2024 plan 2,200 million yen.

It costs ¥4,874 yen per bottle (USD $46.74)

Which is approximately a 2 week supply.

The sales price per bottle in the US will be $750 USD.

So in FY21 in Japan they sold 194,000 bottles. (950million ÷ 4,874) The first year Ecclock (Sofdra) was available.

If they match that first year of sales from Japan in the U.S. that would equate to $145 million USD gross.

No royalties are due to any 3rd party.


Hence you can see why some are predicting $2 - $5 a share.

Are the receipts from customers figures which show up on the quarterly reports solely monies from the 5% royalties due to BOT for Ecclock Kaken Japan?